The effect of omeprazole pre- and cotreatment on cerivastatin absorption and metabolism in man

International Journal of Clinical Pharmacology and Therapeutics

Volumn 36, Issue 10, 1998, Pages 517-520

  Sachse, R ^a,b   Ochmann, K ^a   Rohde, G ^a   Muck W ^a  

^a BAYER AG   (Germany)

^b MEDA Manufacturing GmbH   (Germany)

Author keywords

Absorption; Cerivastatin; Cytochrome p450; Gastric acid secretion inhibitor; HMG CoA reductase inhibitor; Omeprazole; Pharmacokinetic interaction

Indexed keywords

CERIVASTATIN; CYTOCHROME P450; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OMEPRAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; BIOAVAILABILITY; BIOTRANSFORMATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; MALE; METABOLIC INHIBITION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; STATISTICS; STOMACH ACID SECRETION; STOMACH PH; URINARY EXCRETION;

ADULT; ANTI-ULCER AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; MALE; OMEPRAZOLE; PYRIDINES;

EID: 0031718760     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Andersson T 1996 Omeprazole drug interaction studies. Clin Pharmacokinet 31: 9-28
2. Angerbauer R, Bischoff H, Steinke W, Ritter W 1994 BAY w 6228. Drugs Future 19: 537-541
3. Bischoff H, Angerbauer R, Bender J, Bischoff E, Faggiotto A, Petzinna D, Pfitzner J, Porter MC, Schmidt D, Thomas G 1997 Cerivastatin: Pharmaclogy of a novel synthetic and highly active HMG-CoA reductase inhibitor. Atherosclerosis 135: 119-130
4. Boberg M, Angerbauer R, Fey P, Kanhai W, Karl W, Kern A, Ploschke J, Radtke M 1997 Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved. Drug Metab Dispos 25: 321-331
5. Ko JW, Sukhova N, Thacker D, Chen P, Flockhart DA 1997 Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 25: 853-862
6. Krol GJ, Beck GW, Ritter W, Lettieri JT 1993 LC separation and induced fluorometric detection of rivastatin in blood plasma. J Pharm Biomed Anal 11: 1269-1275
7. Meyer UA 1996 Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole, and pantoprazole with other drugs. Eur J Gastroenterol Hepatol 8 (Suppl 1): S21-25
8. Mück W, Ritter W, Ochmann K, Unger S, Ahr G, Windender W, Kuhlmann J 1997a Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin. Int J Clin Pharmacol Ther 35: 255-260
9. Mück W, Ochmann K, Mazzu A, Lettieri J 1997b Biopharmaceutical profile of cerivastatin, a novel HMG-CoA reductase inhibitor. Atherosclerosis 134: 130
10. 2-antagonist cimetidine on the pharmacokinetics of cerivastatin. Int J Clin Pharmacol Ther 35: 261-264
11. Mück W, Ochmann K, Rohde G, Unger S, Kuhlmann J 1998a No drug-drug interaction between cerivastatin and omeprazole. Naunyn-Schmiedebergs Arch Pharmacol 357 (Suppl 4): R175
12. Mück W, Kawano K, Ahr G 1998b Interethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Br J Clin Pharmacol 45: in press
13. Mück W 1998c Thorough assessment of interaction profile supports sate therapeutic use of statins: focus on cerivastatin. Drugs submitted
14. Radtke M, Boberg M, Kanhai W, Kern A, Leega A, Nowak K 1997 Cerivastatin: Identification of human cytochrome P-450 isozymes involved in the biotransformation of the drug and two active metabolites. North American ISSX Meeting, Hilton Head, SC/USA, October 26-30
15. Radtke M, Kanhai W 1998a Characterization of the cytochrome P450 isozymes involved in the metabolism of cerivastatin in humans. Drug Metab Dispos in preparation
16. Radtke M 1998b Determination of the inhibitory potency of cerivastatin and its pharmacologically active metabolites towards human cytochrome P450 isozymes. Drug Metab Dispos in preparation
17. Sachse R, Brendel E, Mück W, Rohde G, Ochmann K, Horstmann R, Kuhlmann J 1998 Lack of drug-drug interaction between cenvastatin and nifedipine. Int J Clin Pharmacol Ther 36: 409-413
18. Stein E, Sprecher D, Allenby KS, Tosiello RL, Whalen E, Ripa SR 1997 Cerivastatin, a new potent synthetic HMG Co-A reductase inhibitor: effect of 0.2 mg daily in subjects with primary hypercholesterolemia. J Cardiovasc Pharmacol Ther 2: 7-16
19. Yang BB, Smithers JA, Abel RB, Stern RH, Sedman AJ, Olson JC 1996 Effects of Maalox TC on pharmacokinetics and pharmacodynamics of atorvastatin. Pharm Res 13 (Suppl): 437